Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

In the 72-week phase 3 ATTAIN-1 trial, the once-daily oral GLP-1 receptor agonist orforglipron led to substantial weight loss ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

A recent study suggests that Eli Lilly's new weight-loss medication helped individuals lose significant amounts of ...

Eli Lilly (LLY) has recently launched SenderraCare+, a digital solution paired with its biologic treatment EBGLYSS, and announced positive outcomes from a Phase 3 trial for the weight management drug ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

For weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares. Industry pioneer Novo ...

A new obesity pill, Orforglipron, shows promise in weight loss trials. Eli Lilly reports that patients lost around 12% of ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...